TB-500 is a synthetic peptide that is a functional analogue of naturally occurring thymosin beta-4 (T\u03b24), a 43-amino acid polypeptide originally discovered in bovine thymus in 1981. TB-500 contains a key actin-binding sequence (LKKTETQ) responsible for the main biological effects of the parent protein, with N-terminal acetylation increasing stability.<\/p>\n
Thymosin \u03b24 is one of the most abundant intracellular proteins in mammals, occurring in high concentrations in all tissues except erythrocytes. Particularly high levels are found in platelets, leukocytes, wound fluid and macrophages – all elements involved in repair processes.<\/p>\n<\/p>\n
The basic mechanism of action of TB-500\/T\u03b24 is based on the regulation of actin dynamics and its consequences for cellular processes:<\/p>\n
G-actin binding and sequestration<\/strong> \u2013 TB-500 binds with high affinity to monomeric G-actin (globular actin), forming a 1:1 complex. This binding prevents spontaneous polymerization of G-actin to F-actin (filamentous actin) and regulates the availability of monomers for controlled cytoskeletal remodeling. G-actin sequestration is crucial for cell migration, cell shape change and cell division.<\/p>\n Cell migration promotion<\/strong> \u2013 By regulating actin, TB-500 increases the ability of cells to migrate towards the site of damage. This effect affects many cell types: keratinocytes, fibroblasts, endothelial cells, myoblasts and stem\/progenitor cells.<\/p>\n Stimulation of angiogenesis<\/strong> \u2013 TB-500 promotes the formation of new blood vessels by stimulating the migration of endothelial cells, creating capillary-like structures and increasing the density of microvessels in tissues. This mechanism is particularly important for the healing of tissues with poor vascularization (tendons, cartilage).<\/p>\n Anti-inflammatory effect<\/strong> \u2013 The sulfoxide form of thymosin \u03b24 (T\u03b24-SO) blocks neutrophil chemotaxis and has anti-inflammatory effects in vivo. TB-500 inhibits the release of pro-inflammatory cytokines and may modulate NF-\u03baB activity.<\/p>\n Anti-apoptotic effect<\/strong> \u2013 TB-500 protects cells against apoptosis by increasing the expression of BCL-2 and reducing the activation of caspases, in part by preventing the release of cytochrome c from mitochondria.<\/p>\n Reduce Fibrosis<\/strong> \u2013 In wound healing processes, TB-500 reduces the number of myofibroblasts, which leads to less scar formation and fibrosis. This mechanism is important for maintaining the functionality of regenerated tissues.<\/p>\n Thymosin \u03b24 (and its synthetic analogue TB-500) is the subject of extensive preclinical research and limited clinical trials.<\/p>\n Wound healing research<\/p>\n The foundational study by Philp et al. (1999) showed that local or intraperitoneal administration of T\u03b24 accelerated wound reepithelialization in rats by 42% after 4 days and up to 61% after 7 days compared to controls. Wounds treated with T\u03b24 also showed increased narrowing (contraction), greater collagen deposition, and enhanced angiogenesis. In in vitro studies, T\u03b24 stimulated keratinocyte migration 2-3 times at concentrations as low as 10 pg. These effects were confirmed in diabetic (db\/db) and aged mice, where a 7-amino-acid synthetic peptide based on the actin-binding domain (TB-500 equivalent) promoted repair comparable to the full parent molecule.<\/p>\n Muscle regeneration research<\/p>\n Research by Hara et al. showed that T\u03b24 acts as a chemoattractant for myoblasts (muscle precursor cells). T\u03b24 and thymosin \u03b210 mRNA levels are increased in the early stages of skeletal muscle regeneration in mice. Both T\u03b24 and its sulfoxide form accelerated wound closure and increased chemotaxis of the C2C12 myoblastic line and primary myoblasts and myocytes derived from adult mouse muscle satellite cells.<\/p>\n Cardiac tests<\/p>\n Thymosin \u03b24 is expressed in the developing heart and adult myocardium (endothelium, epicardium, coronary endothelium). Preclinical studies in models of myocardial infarction have shown:<\/p>\n The mechanism includes promotion of cardiac angiogenesis, reduction of inflammatory damage, and stimulation of cardiomyocyte survival pathways.<\/p>\n Ophthalmological examinations<\/p>\n Thymosin \u03b24 is intensively studied in the context of corneal wound healing and Pseudomonas aeruginosa-induced keratitis. The peptide exerts anti-inflammatory effects by inhibiting NF-\u03baB in corneal endothelial cells. Phase II clinical trials have been conducted with T\u03b24 in corneal regeneration.<\/p>\n Sepsis research<\/p>\n In septic conditions, an increased level of free F-actin in the blood (F-actinemia) is observed, which can damage the endothelium and form microthrombi. T\u03b24, as an actin-binding protein, inhibits F-actin polymerization and is being investigated as a potential protective factor in sepsis.<\/p>\n Dermatological tests – clinical trials<\/p>\n In Phase II clinical trials, T\u03b24 (RGN-259, RegeneRx Biopharmaceuticals) promoted the healing of venous stasis ulcers and showed potential in the treatment of epidermolysis bullosa and other severe skin lesions.<\/p>\n TB-500\/Thymosin \u03b24 fits into the concept of “reminding adult organs of their embryonic state” – the peptide plays a key role in the embryonic development of the heart, brain, eyes and limbs, and its exogenous administration can reactivate regenerative processes in adult tissues.<\/p>\n Compared to other regenerative peptides:<\/p>\n These two peptides are often used together by researchers due to their complementary mechanisms of action – TB-500 promotes cell migration to the site of damage, BPC-157 supports angiogenesis and modulates signaling pathways.<\/p>\n Thymosin \u03b24 and TB-500 are on the WADA Prohibited Substances List as agents that promote tissue regeneration and potentially improve athletic performance.<\/p>\n In preclinical studies, thymosin \u03b24 showed a favorable safety profile without significant toxic effects. Peptide is a natural component of the body, present in high concentrations in many tissues.<\/p>\n No serious adverse events related to therapy were reported in limited clinical studies (mainly dermatology and ophthalmology).<\/p>\n Potential theoretical concerns:<\/strong><\/p>\n Synthetic fragment of thymosin \u03b24 | Actin regulator<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"product_brand":[],"product_cat":[56],"product_tag":[],"class_list":["post-210","product","type-product","status-publish","product_cat-badania-regeneracji-i-gojenia","first","instock","taxable","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/product\/210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/types\/product"}],"wp:attachment":[{"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/media?parent=210"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/product_brand?post=210"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/product_cat?post=210"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/pl\/wp-json\/wp\/v2\/product_tag?post=210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Directions of scientific research<\/h3>\n
\n
Scientific context<\/h3>\n
\n
Research safety profile<\/h3>\n
\n
Bibliography – latest scientific research<\/h3>\n
\n